

Application of an Organozinc Reagent Derived from (S)-Pyroglutamic Acid: a Formal Synthesis of Epibatidine

Willem F. J. Karstens, Marinus J. Moolenaar, Floris P. J. T. Rutjes,
Urszula Grabowska, W. Nico Speckamp and Henk Hiemstra*

Laboratory of Organic Chemistry, Institute of Molecular Chemistry, University of Amsterdam
Nieuwe Achtergracht 129, 1018 WS Amsterdam, The Netherlands


Received 23 August 1999; accepted 22 September 1999

Abstract

A formal total synthesis of natural (–)-epibatidine has been developed. Key steps in the synthesis are a copper(I)-mediated coupling of an (S)-pyroglutamic acid-derived organozinc reagent with 1-iodo-3-trimethylsilyl-1-propyne and an *N*-acyl- or *N*-sulfonyliminium ion cyclization. Following this route, various *N*-protected hydroxylactams were converted into 7-azabicyclo[2.2.1]heptane derivatives. © 1999 Elsevier Science Ltd. All rights reserved.

Keywords: epibatidine; organozinc reagent; *N*-acyliminium ions; azabicyclo[2.2.1]heptanes.


The general interest in the 7-azabicyclo[2.2.1]heptane skeleton has seen a strong revival¹ since the structural elucidation of (–)-epibatidine **1**,² isolated from the Ecuadorian neotropical frog *Epipedobates tricolor*. Among its remarkable biological properties³ are the exceptionally strong analgesic activity and the high affinity for the nicotinic receptors.



Most reported syntheses describe the preparation of racemic **1**,⁴ while in some cases the incorporation of a resolution step leads to enantiomerically pure material.⁵ Since the determination of the absolute stereochemistry of the natural compound,^{5b} special attention has been paid to the direct preparation of enantiomerically pure **1**.⁶ Our own interest in bridged azabicyclo compounds stems from the synthesis of the

* Corresponding author. Fax: +31 20 525 5670; E-mail: henkh@org.chem.uva.nl

alkaloid ($\pm$)-anatoxine-a⁷ and from the synthesis of enantiopure azatropane and aza-cocaine analogues.⁸ In these cases, we used our *N*-acyliminium ion cyclization methodology⁹ to construct the bicyclic skeleton of the target molecules. In conjunction with this work, we present a concise and straightforward synthesis of the enantiopure ketones **2a–c** (eq 1, **2a**: R = methoxycarbonyl, **2b**: R = Boc, **2c**: R = Ts), of which **2b**^{5b} and **2c**^{4b} have been previously converted into epibatidine. Key steps in our synthesis are the coupling reaction of the (*S*)-pyroglutamic acid-derived organozinc reagent **4** with 1-iodo-3-trimethylsilyl-1-propyne and the *N*-acyl- or *N*-sulfonyliminium ion cyclization of the *N,O*-acetals **3**. This cationic cyclization is somewhat reminiscent of the radical approach used by Clive and coworkers⁶ⁱ in the synthesis of (–)-**2b**.



Previously, we successfully applied organozinc reagent **4** (derived from **5**¹⁰ by treatment with activated Zn in DMF) for the preparation of several enantiopure allene-substituted lactams by means of an $\text{S}_{\text{N}}2'$ -displacement of propargylic tosylates.¹¹ More recently, we set out to further explore the chemistry of this versatile reagent. For example, reaction with bromoallene¹² in the presence of CuCN·2LiCl led to the acetylenic lactam **6** in 52% yield (eq 2). The analogous propargylic lactam **7** was obtained in the same yield by subjecting 1-iodo-1-heptyne to these conditions.¹³ Thus being able to generate propargyl-substituted lactams in an efficient manner, we reasoned that it should be possible to prepare the propargylsilane-substituted lactam **8** – a projected intermediate in a synthesis of epibatidine – in a similar manner. In previous experiments, we were unable to react higher order cuprates derived from propargyltrimethylsilane with pyrrolidinones **5** (or the corresponding bromide) to arrive at **8** despite the fact that this reaction works well for aliphatic and aromatic cuprates.¹⁴ By applying the organozinc reagent **4**, however, after transmetalation with CuCN·2LiCl and reaction with 1-iodo-3-trimethylsilyl-1-propyne¹⁵ the desired lactam **8** was formed in a respectable 49% yield. Straightforward acylation or tosylation, followed by partial reduction of the lactam carbonyl to give the *N,O*-acetals **3** now set the stage for the intramolecular *N*-acyl- or *N*-tosyliminium ion cyclization reaction (Table 1).¹⁶

Table 1

	9	3	10	2
a : R = CO ₂ Me	89%	95%		96%
b : R = Boc	97%	97%		93%
c : R = Ts	94%	95%		79%
d : R = Alloc	88%	96%		-

Reagents and conditions: (a) 1. **9a**: 1. LDA (1.1 equiv), –78 °C; 2. NCCOOMe –78 °C to rt; **9b**: Boc₂O, Et₃N, DMAP; **9c,d**: *n*-BuLi (1.1 equiv), THF; 2. RCl (1.2 equiv); (b) DIBAL-H (2 equiv), THF, –78 °C, 1 h; (c) HCO₂H, 0 °C to rt, 10 min; (d) 1. O₃, –78 °C, CH₂Cl₂, 10 min; 2. SiMe₂, rt, 2 h.

On stirring the *N,O*-acetals **3** in formic acid a silicon-assisted cyclization *via* the cationic species **10** went to completion within a few minutes to produce the allenic bicyclic heptanes **11a** and **11c** in a clean reaction. Unfortunately, the *tert*-butyl and allyl carbamates **11b** and **11d** were only obtained in low yields, probably due to deprotection and other side reactions. The cyclizations were quenched (NaHCO₃) after 10 min, because prolonged exposure to formic acid led to partial solvolysis of the allene moiety. The allenes **11a–c** were then

treated with ozone in CH_2Cl_2 at -78°C to give ketones **2a–c** in good to excellent yields, thus constituting (in the case of **2b** and **2c**) a formal synthesis of (–)-epibatidine.

In summary, we have further demonstrated the usefulness of an (S)-pyroglutamic acid-derived organozinc reagent via the synthesis of acetylene-substituted lactams. As an application, a highly efficient formal synthesis of (–)-epibatidine was developed involving as the key steps a copper(I)-mediated coupling of this zinc reagent to generate a propargylsilane-substituted lactam and an *N*-acyl- or an *N*-sulfonyliminium ion cyclization to construct the bicyclic skeleton.

Acknowledgment

N.V. Organon, Oss, The Netherlands (Prof. H. C. J. Ottenheijm) is kindly acknowledged for providing financial support. This research has been financially supported by the Council for Chemical Sciences of the Netherlands Organization for Scientific Research (CW-NWO).

References

- 1) For a review, see: Chen, Z.; Trudell, M. L. *Chem. Rev.* **1996**, *96*, 1179.
- 2) (a) Spande, T. F.; Garraffo, H. M.; Edwards, M. W.; Yeh, H. J. C.; Pannell, L.; Daly, J. W. *J. Am. Chem. Soc.* **1992**, *114*, 3475; (b) Badio, B.; Garraffo, H. M.; Spande, T. F.; Daly, J. W. *Med. Chem. Res.* **1994**, *4*, 440.
- 3) (a) Badio, B.; Daly, J. W. *Mol. Pharmacol.* **1994**, *45*, 563; (b) Bannon, A. W.; Decker, M. W.; Holladay, M. W.; Curzon, P.; Donnelly-Roberts, D.; Puttfarcken, P. S.; Bitner, R. S.; Diaz, A.; Dickenson, A. H.; Porsolt, R. D.; Williams, M.; Armer, S. P. *Science* **1998**, *279*, 77.
- 4) (a) Clayton, S. C.; Regan, A. C. *Tetrahedron Lett.* **1993**, *34*, 7493; (b) Huang, D. F.; Shen, T. Y. *Tetrahedron Lett.* **1993**, *34*, 4477; (c) Fletcher, S. R.; Baker, R.; Chambers, M. S.; Hobbs, S. C.; Mitchell, P. J. *J. Chem. Soc., Chem. Commun.* **1993**, 1216; (d) Broka, C. A. *Tetrahedron Lett.* **1993**, *34*, 3251; (e) Sestan, K.; Melenski, E.; Jirkovsky, I. *Tetrahedron Lett.* **1994**, *35*, 5417; (f) Ko, S. Y.; Lerpiniere, J.; Linney, I. D.; Wrigglesworth, R. J. *J. Chem. Soc., Chem. Commun.* **1994**, 1775; (g) Okabe, K.; Natsume, M. *Chem. Pharm. Bull.* **1994**, *42*, 1432; (h) Zhang, C.; Trudell, M. L. *J. Org. Chem.* **1996**, *61*, 7189; (i) Liang, F.; Navarro, H. A.; Abraham, P.; Kotian, P.; Ding, Y.-S.; Fowler, J.; Volkow, N.; Kuhar, M. J.; Carroll, F. I. *J. Med. Chem.* **1997**, *40*, 2293; (j) Singh, S.; Basmadjian, G. P. *Tetrahedron Lett.* **1997**, *38*, 6829; (k) Pavri, N. P.; Trudell, M. L. *Tetrahedron Lett.* **1997**, *38*, 7993; (l) Ikeda, M.; Kugo, Y.; Kondo, Y.; Yamazaki, T.; Sato, T. *J. Chem. Soc., Perkin Trans. 1* **1997**, 3339; (m) Seerden, J.-P. G.; Tulp, M. Th. M.; Scheeren, H. W.; Kruse, C. G. *Bioorg. Med. Chem.* **1998**, *6*, 2103; (n) Cabanal-Duvillard, I.; Berrien, J.-F.; Royer, J.; Husson, H.-P. *Tetrahedron Lett.* **1998**, *39*, 5181; (o) Avenoza, A.; Busto, J. H.; Cativiela, C.; Peregrina, J. M.; *Synthesis* **1998**, 1335; (p) Sirisoma, N. S.; Johnson, C. R. *Tetrahedron Lett.* **1998**, *39*, 2059; (q) Panday, G.; Bagul, T.D.; Sahoo, A. K. *J. Org. Chem.* **1998**, *63*, 760; (r) Zhang, C.; Ballay II, C. J.; Trudell, M. L. *J. Chem. Soc., Perkin Trans. 1* **1999**, 675; (s) Palmgren, A.; Larsson, A. L. E.; Bäckvall, J.-E. *J. Org. Chem.* **1999**, *64*, 836.
- 5) (a) Corey, E. J.; Loh, T.-P.; AchyuthaRao, S.; Daley, D. C.; Sarshar, S. *J. Org. Chem.* **1993**, *58*, 5600; (b) Fletcher, S. R.; Baker, R.; Chambers, M. S.; Herbert, R. H.; Hobbs, S. C.; Thomas, S. R.; Verrier, H. M.; Watt, A. P.; Ball, R. G. *J. Org. Chem.* **1994**, *59*, 1771; (c) Kotian, P. L.; Carroll, F. I. *Synth. Commun.* **1995**, *25*, 63; (d) Szántay, C.; Kardos-Balogh, Z.; Moldvai, I.; Szántay Jr., C.; Temesvári-Major, E.; Blaskó, G. *Tetrahedron* **1996**, *52*, 11053.
- 6) (a) Hernandez, A.; Marcos, M.; Rapoport, H. *J. Org. Chem.* **1995**, *60*, 2683; (b) Campbell, J. A.; Rapoport, H. *J. Org. Chem.* **1996**, *61*, 6313; (c) Trost, B. M.; Cook, G. R. *Tetrahedron Lett.* **1996**, *37*, 7485; (d) Kosugi, H.; Abe, M.; Hatsuda, R.; Uda, H.; Kato, M. *J. Chem. Soc., Chem. Commun.* **1997**, 1857; (e) Albertini, E.; Barco, A.; Benetti, S.; De Risi, C.; Pollini, G.P.; Zanirato, V. *Tetrahedron*, **1997**, *53*, 17177; (f) Olivo, H.F.; Hemenway, M. S.; Gezgin, M. H. *Tetrahedron Lett.* **1998**, *39*, 1309; (g) Giblin, G. M. P.; Jones, C. D.; Simpkins, N. S. *J. Chem. Soc., Perkin Trans. 1* **1998**, 3689; (h) Aoyagi, S.; Tanaka, R.; Naruse, M.; Kibayashi, C. *J. Org. Chem.* **1998**, *63*, 8397; (i) Clive, D. L. J.; Yeh, V. S. C. *Tetrahedron Lett.* **1998**, *39*, 4789.
- 7) Esch, P. M.; Hiemstra, H.; Klaver, W. J.; Speckamp, W. N. *Heterocycles* **1987**, *26*, 75.
- 8) Teerhuis, N. M.; Hiemstra, H.; Speckamp, W. N. *Tetrahedron Lett.* **1997**, *38*, 155, 159.
- 9) For reviews, see: (a) De Koning, H.; Moolenaar, M. J.; Hiemstra, H.; Speckamp, W. N. in *Studies in Natural Products Chemistry*, Atta-ur-Rahman Ed.; Elsevier: Amsterdam, 1993, Vol. 13, p 473; (b) Hiemstra, H.; Speckamp, W. N. in *Comprehensive Organic Synthesis* Trost, B. M., Fleming, I. Eds.; Pergamon: Oxford,

- 1991, Vol. 2, p 1047; (c) Hiemstra, H.; Speckamp, W. N. in *The Alkaloids*, Brossi, A. Ed.; Academic Press: New York, 1988, Vol. 32, p 271.
- 10) (a) Provot, O.; Célérier, J. P.; Petit, H.; Lhommet, G. *J. Org. Chem.* **1992**, *57*, 2163; (b) Holmes, A. B.; Smith, A. L.; Williams, S. F.; Hughes, L. R.; Lidert, Z.; Swithenbank, C. *J. Org. Chem.* **1991**, *57*, 1393.
 - 11) Karstens, W. F. J.; Stol, M.; Rutjes, F. P. J. T.; Hiemstra, H. *Synlett* **1998**, 1126.
 - 12) Brandsma, L.; Verkruijsse, H. D. *Synth. Commun.* **1991**, *21*, 69.
 - 13) (a) Yeh, M. C. P.; Knochel, P. *Tetrahedron Lett.* **1989**, *30*, 4799; (b) Duddu, J.; Eckhardt, M.; Furlong, H.; Knoess, H. P.; Berger, S.; Knochel, P. *Tetrahedron* **1994**, *50*, 2115.
 - 14) (a) Winkler, J. D.; Hershberger, P. M. *J. Am. Chem. Soc.* **1989**, *111*, 4852; (b) Matthes, M.; Tamm, C. *Helv. Chim. Acta* **1991**, *74*, 1585; (c) Ackermann, J.; Matthes, M.; Tamm, C. *Helv. Chim. Acta* **1990**, *73*, 122.
 - 15) Kabbara, J.; Hoffmann, C.; Schinzer, D. *Synthesis* **1995**, 299.
 - 16) A typical experimental sequence proceeded as follows (4 → 2c):
 (S)-5-[4-(Trimethylsilyl)but-2-ynyl]pyrrolidin-2-one (**8**): To a mixture of dry LiCl (848 mg, 20 mmol) in THF (50 mL) was added CuCN (896 mg, 10 mmol). The resulting solution was cooled to -40 °C and treated dropwise with a solution of organozinc reagent **4**¹¹ (prepared from (S)-5-iodomethylpyrrolidin-2-one **5** (10 mmol) in DMF (10 mL). The mixture was stirred at 0 °C for 10 min, recooled to -30 °C and 1-iodo-3-trimethylsilyl-1-propyne (2.38 g, 10 mmol) was slowly added by syringe. The mixture was stirred at -30 °C for 4 h and then allowed to reach ambient temperature overnight. After the addition of saturated aqueous NH₄Cl (100 mL), the aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic layers were dried (Na₂SO₄), concentrated and purified by flash column chromatography (5% MeOH in EtOAc) to give pure **8** as a white solid (1.03 g, 4.92 mmol, 49%): mp 68-69 °C; [α]_D -48 (c 0.7, MeOH); IR (CHCl₃) ν 3430, 3000, 2960, 2900, 2215, 1685, 1250, 840; ¹H NMR (400 MHz, CDCl₃) δ 6.02 (br s, 1H), 3.78-3.72 (m, 1H), 2.43-2.19 (m, 5H), 1.88-1.79 (m, 1H), 1.42, (t, J = 2.6 Hz, 2H), 0.08 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 177.6, 80.2, 73.9, 53.7, 29.9, 26.8, 26.2, 6.9, -2.2; HRMS (EI) calcd for C₁₁H₁₉NOSi 209.1236, found 209.1226.
 (S)-N-(p-Toluenesulfonyl)-5-[4-(trimethylsilyl)but-2-ynyl]-pyrrolidin-2-one (**9c**): To a solution of **8** (302 mg, 1.44 mmol) in THF (2.5 mL) at -78 °C was slowly added n-BuLi (1.0 mL, 1.6 M in hexanes). After stirring for 30 min at -78 °C, TsCl (303 mg, 1.59 mmol) was added and the reaction mixture was allowed to attain room temperature. Quenching with saturated aqueous NH₄Cl (10 mL), dilution with Et₂O (25 mL), washing with brine (15 mL), drying (Na₂SO₄) and purification by flash chromatography (EtOAc/hexanes 1:4) yielded **9c** as a colorless oil (491 mg, 1.39 mmol, 94%): [α]_D -111 (c 0.9, CHCl₃); IR (neat) ν 2956, 2221, 1733, 1360, 1169; ¹H NMR (400 MHz, CDCl₃) δ 7.91 (d, J = 8.3 Hz, 2H), 7.28 (d, J = 8.3 Hz, 2H), 4.45-4.40 (m, 1H), 2.75-2.59 (m, 3H), 2.39 (s, 3H), 2.34-2.16 (m, 2H), 2.08-2.02 (m, 1H), 1.28 (t, J = 2.6 Hz, 2H), -0.01 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 173.5, 144.7, 135.7, 129.3, 128.3, 81.1, 72.8, 58.6, 30.7, 25.5, 23.5, 21.5, 6.8, -2.2. HRMS (FAB) calcd for C₁₈H₂₆NO₃SSi (M + 1): 364.1403, found 364.1413.
 (1R,4S)-N-(p-Toluenesulfonyl)-2-vinylidene-7-azabicyclo-[2.2.1]-heptane (**11c**): To a solution of **9c** (432 mg, 1.22 mmol) in THF (5.0 mL) at -78 °C was slowly added DIBAL-H (1.22 mL, 1.5 M in toluene) and the reaction was allowed to reach completion (1 h, -78 °C). A few drops of saturated aqueous Na₂SO₄ and EtOAc (20 mL) were added to the reaction and the resulting mixture was stirred at rt for 1 h. The mixture was filtered over Celite and concentrated *in vacuo*. The crude compound **3c** (413 mg, 1.16 mmol, 95%) was dissolved in ice-cold formic acid (2 mL) and stirred for 10 min, reaching room temperature. The mixture was poured into saturated NaHCO₃ (30 mL), extracted with Et₂O (3 × 10 mL), washed with brine (10 mL), dried (Na₂SO₄) and purified by flash chromatography to give **11c** as a white crystalline solid (238 mg, 0.86 mmol, 75%): mp 135-136 °C; [α]_D -147 (c 0.9, CHCl₃); IR (CHCl₃) ν 3030, 2957, 1972, 1340, 1151; ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, J = 8.2 Hz, 2H), 7.26 (d, J = 8.2 Hz, 2H), 4.69-4.64 (m, 2H), 4.57 (br d, J = 4.3 Hz, 1H), 4.25 (br t, J = 4.5 Hz, 1H), 2.41 (s, 3H), 2.25-2.18 (m, 1H), 2.06-1.89 (m, 3H), 1.68 (m, 1H), 1.49-1.42 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 200.0, 143.6, 136.7, 129.2, 128.0, 100.7, 78.2, 62.9, 59.7, 36.5, 30.8, 29.8, 21.5; Anal.: Calcd for C₁₅H₁₇NO₃S: C, 65.43; H, 6.22; N, 5.09. Found: C, 65.37; H, 6.15; N, 5.03.
 (1R,4S)-N-(p-Toluenesulfonyl)-7-azabicyclo-[2.2.1]-heptan-2-one (**2c**): Standard ozonolysis of **11c** (200 mg, 0.73 mmol) in CH₂Cl₂ (10 mL) at -78 °C (10 min), followed by stirring with dimethyl sulfide (5 mL) at room temperature for 2 h gave ketone **2c** as a white crystalline solid (152 mg, 0.57 mmol, 79%): mp 127.5-128.0 °C; [α]_D -66 (c 1.0, CHCl₃); Anal. Calcd for C₁₃H₁₅NO₃S: C, 58.85; H, 5.70; N, 5.28. Found: C, 58.79; H, 5.65; N, 5.23. All other spectroscopic data were identical to those described in the literature.⁴⁸